1. A class action lawsuit against LifeMD has been announced. 2. Lawsuit claims LifeMD overstated competitive position and guidance for 2025. 3. Company shares lost 44% of value after financial truths revealed. 4. Investors have until October 27, 2025, to join as lead plaintiffs. 5. LifeMD provides telehealth services, including obesity treatments.
The class action lawsuit indicates serious financial mismanagement, leading to steep declines in share value historically. A similar case can be seen in companies that mismanaged investor communications, resulting in significant stock price drops.
Given the severity of the allegations and potential implications, this news is crucial for current and potential investors in LFMD, indicating a heightened risk environment.
Immediate investor reactions to the lawsuit will likely drive stock volatility in the next few weeks. Historical examples reflect rapid shifts in stock prices during active litigation periods.
PHILADELPHIA, Aug. 28, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against LifeMD, Inc. (NASDAQ:LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period").
Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
LifeMD is a direct-to-consumer telehealth company headquartered in New York, New York. The Company provides virtual healthcare services and pharmacy offerings across areas including men's health, obesity treatment, and chronic care.
The complaint alleges the Company materially overstated its competitive position and was reckless in raising its 2025 guidance, failing to properly account for rising customer acquisition costs in both its RexMD segment and its obesity drug offerings, including Wegovy and Zepbound.
When the truth about the Company's finances were revealed, LifeMD shares lost 44% of their value in a single trading session.
If you are a LifeMD investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Director of Portfolio and Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-lifemd-inc-nasdaq-lfmd-investors-after-class-action-filing-302541538.html
SOURCE Berger Montague